Detalhe da pesquisa
1.
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Breast Cancer Res Treat
; 204(1): 123-132, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38019444
2.
Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
Ann Surg Oncol
; 31(4): 2244-2252, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38161200
3.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Lancet Oncol
; 24(3): 273-285, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858723
4.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
J Natl Compr Canc Netw
; 21(6): 594-608, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37308117
5.
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
Cancer
; 128 Suppl 11: 2209-2223, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35536015
6.
Postneoadjuvant treatment for triple-negative breast cancer.
Curr Opin Oncol
; 34(6): 623-634, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35993306
7.
Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.
Ann Surg Oncol
; 29(12): 7674-7682, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35763229
8.
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.
Ann Surg Oncol
; 29(13): 8016-8023, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35900648
9.
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(6): 691-722, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714673
10.
Multidisciplinary considerations in the treatment of triple-negative breast cancer.
CA Cancer J Clin
; 70(6): 432-442, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32986241
11.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 22(2): 212-222, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33460574
12.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863451
13.
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
Breast Cancer Res Treat
; 185(1): 135-144, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33025482
14.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34120223
15.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
J Natl Compr Canc Netw
; 19(5): 484-493, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794122
16.
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Breast Cancer Res Treat
; 181(2): 347-359, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32274665
17.
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.
Breast Cancer Res Treat
; 181(3): 487-497, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32333293
18.
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(4): 452-478, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32259783
19.
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply.
N Engl J Med
; 384(12): 1176-1177, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761226
20.
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Breast Cancer Res Treat
; 176(2): 303-310, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31004299